Surgery plus targeted radiation for prostate cancer spread
Treatments studied
Part of Cancer clinical trials.
This study looks at whether combining prostate surgery with a highly focused radiation treatment (SBRT) can control prostate cancer that has spread to a limited number of bones. It may help patients by treating the main tumor and the specific metastatic spots in a controlled way.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 years or older and can give informed consent
- Your prostate cancer can be removed by surgery (your team says it’s resectable)
- Your cancer is at stage cT1 through cT3b and your Gleason score is 6 or higher
- Your cancer has spread (M1) but only to up to 3 bone spots in certain areas, with no organ (visceral) spread
- Your scans show no spread to certain lymph nodes (retroperitoneal lymph nodes), and the bone spots are suitable for SBRT
- You must not have had curative prostate cancer treatment before, and you must not have started hormone therapy (ADT) yet
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at whether a precise form of radiation (stereotactic body radiotherapy) can control a small number of prostate cancer spots seen on a special scan (PSMA PET/CT). It may help by treating limited metastases while avoiding unnecessary treatment elsewhere.
This Phase 3 trial tests whether treating only a small number of prostate cancer metastases can help people with “oligorecurrent” (limited repeat) prostate cancer. It may reduce cancer activity while avoiding broader whole-body treatment for some patients.
This trial tests two newer treatments—targeted radiation (SABR) or a special radioactive drug (Lu-177 PSMA-617)—added to standard hormone therapy for men with prostate cancer that has spread. The goal is to see if these additional treatments help control the cancer better.
This trial studies whether adding focused radiation (SBRT) to hormone therapy can control prostate cancer that has spread to only a few places. It aims to help people with early “oligometastatic” prostate cancer by improving disease control while limiting treatment side effects.
This trial tests whether adding radiation therapy to the prostate and cancer spread sites helps men whose prostate cancer has spread to bones but isn't responding well to standard hormone treatments. You'd be eligible if your PSA level (a cancer marker) stays high after six months of dual hormone therapy.
This study tests whether adding a type of high-precision radiation (MDRT) to standard hormone therapy works better for men with prostate cancer that has spread to just a few places. It is for patients who are newly diagnosed and on long-term hormone therapy.
Hear when a new Prostate Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.